Trametinib: risk of gastrointestinal perforation and colitis

The melanoma treatment trametinib (Mekinist) can cause gastrointestinal perforation or colitis, the MHRA has highlighted.

Trametinib is licensed for the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation. | SCIENCE PHOTO LIBRARY
Trametinib is licensed for the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation. | SCIENCE PHOTO LIBRARY

Trametinib, authorised either as monotherapy or in combination with dabrafenib to treat unresectable or metastatic melanoma with a BRAF V600 mutation, should be used with caution in patients with risk factors for gastrointestinal perforation. Such risk factors include gastrointestinal metastases, diverticulitis, or use of concomitant medicines that can cause gastrointestinal perforation.

Further information
View Mekinist drug record
Summary of Product Characteristics
MHRA Drug Safety Update

Patients being treated with trametinib should be advised to seek medical help immediately if they develop severe abdominal pain.

All serious suspected adverse reactions associated with trametinib should be reported in accordance with the MHRA Yellow Card Scheme.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in